AIM: To assess the pharmacokinetic effect and tolerability of lamotrigine 200 mg day(-1) and olanzapine 15 mg day(-1) coadministration in healthy male volunteers. METHODS: Subjects were randomized to receive either lamotrigine titrated on days 1-42 with olanzapine added on days 43-56 (LTG + OLZ group; N = 16), lamotrigine titration with placebo added on days 43-56 (LTG group; N = 12), or placebo on days 1-42 with olanzapine added on days 43-56 (OLZ group; N = 16). Steady state (0-24 h) pharmacokinetic profiles were determined on day 56 in each group. RESULTS: The average (90% confidence interval) ratios of lamotrigine area under the concentration-time curve from 0 to 24 h and maximum observed concentration for the comparison of LTG + OLZ:LTG were 0.76 (0.65, 0.90) and 0.80 (0.71, 0.90), respectively. Olanzapine pharmacokinetics were essentially unaffected by lamotrigine. The most frequently reported adverse events (AEs) during combination therapy were fatigue, dizziness and mild transaminase elevations. These AEs occurred at similar frequencies in the LTG + OLZ and OLZ cohorts, while being less frequent or absent in the LTG group. CONCLUSIONS:Lamotrigine and olanzapine coadministration in patients who may benefit from the combination was supported by this study. Lamotrigine dosing schedules are recommended to remain unchanged when combined with olanzapine therapy. However, the possibility exists that the lamotrigine dose for some patients may need adjustment to optimize treatment when olanzapine is added to or withdrawn from a regimen including lamotrigine.
RCT Entities:
AIM: To assess the pharmacokinetic effect and tolerability of lamotrigine 200 mg day(-1) and olanzapine 15 mg day(-1) coadministration in healthy male volunteers. METHODS: Subjects were randomized to receive either lamotrigine titrated on days 1-42 with olanzapine added on days 43-56 (LTG + OLZ group; N = 16), lamotrigine titration with placebo added on days 43-56 (LTG group; N = 12), or placebo on days 1-42 with olanzapine added on days 43-56 (OLZ group; N = 16). Steady state (0-24 h) pharmacokinetic profiles were determined on day 56 in each group. RESULTS: The average (90% confidence interval) ratios of lamotrigine area under the concentration-time curve from 0 to 24 h and maximum observed concentration for the comparison of LTG + OLZ:LTG were 0.76 (0.65, 0.90) and 0.80 (0.71, 0.90), respectively. Olanzapine pharmacokinetics were essentially unaffected by lamotrigine. The most frequently reported adverse events (AEs) during combination therapy were fatigue, dizziness and mild transaminase elevations. These AEs occurred at similar frequencies in the LTG + OLZ and OLZ cohorts, while being less frequent or absent in the LTG group. CONCLUSIONS:Lamotrigine and olanzapine coadministration in patients who may benefit from the combination was supported by this study. Lamotrigine dosing schedules are recommended to remain unchanged when combined with olanzapine therapy. However, the possibility exists that the lamotrigine dose for some patients may need adjustment to optimize treatment when olanzapine is added to or withdrawn from a regimen including lamotrigine.
Authors: Mauricio Tohen; Joseph F Goldberg; Ana Maria Gonzalez-Pinto Arrillaga; Jean M Azorin; Eduard Vieta; Marie-Christine Hardy-Bayle; William B Lawson; Robin A Emsley; Fan Zhang; Robert W Baker; Richard C Risser; Madhav A Namjoshi; Angela R Evans; Alan Breier Journal: Arch Gen Psychiatry Date: 2003-12
Authors: Charles L Bowden; Joseph R Calabrese; Gary Sachs; Lakshmi N Yatham; Shaheen Akthar Asghar; Magne Hompland; Paul Montgomery; Nancy Earl; Tonya M Smoot; Joseph DeVeaugh-Geiss Journal: Arch Gen Psychiatry Date: 2003-04
Authors: Guy M Goodwin; Charles L Bowden; Joseph R Calabrese; Heinz Grunze; Siegfried Kasper; Robin White; Paul Greene; Robert Leadbetter Journal: J Clin Psychiatry Date: 2004-03 Impact factor: 4.384
Authors: Ross J Baldessarini; John Hennen; Michael Wilson; Joseph Calabrese; Roy Chengappa; Paul E Keck; Susan L McElroy; Gary Sachs; Eduard Vieta; Jeffrey A Welge; Lakshmi N Yatham; Carlos A Zarate; Robert W Baker; Mauricio Tohen Journal: J Clin Psychopharmacol Date: 2003-08 Impact factor: 3.153
Authors: R E Ramsay; J M Pellock; W R Garnett; R M Sanchez; A M Valakas; W A Wargin; A A Lai; J Hubbell; W H Chern; T Allsup Journal: Epilepsy Res Date: 1991 Nov-Dec Impact factor: 3.045
Authors: Joseph R Calabrese; Charles L Bowden; Gary Sachs; Lakshmi N Yatham; Kirsten Behnke; Olli-Pekka Mehtonen; Paul Montgomery; John Ascher; Walter Paska; Nancy Earl; Joseph DeVeaugh-Geiss Journal: J Clin Psychiatry Date: 2003-09 Impact factor: 4.384